Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC

NCT01214343 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

190

Enrollment

OTHER_GOV

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma
Carcinoma
Carcinoma, Hepatocellular
Liver Neoplasms
Neoplasms

Interventions

DRUG: Sorafenib with Low-dose FP
DRUG: Sorafenib

Sponsor

Ministry of Health, Labour and Welfare, Japan